Journal articles: 'Infections à Burkholderia – Thérapeutique'

1

Rao, P. Sugandhi, Reetika Dhawan, and P. G. Shivananda. "Burkholderia Pseudomallei Infections." Tropical Doctor 32, no. 3 (July 2002): 174–75. http://dx.doi.org/10.1177/004947550203200321.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Dance, D. A. B. "Burkholderia pseudomallei Infections." Clinical Infectious Diseases 30, no. 1 (January 1, 2000): 235–36. http://dx.doi.org/10.1086/313577.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Bertholom, Chantal. "Infections associées aux Burkholderia." Option/Bio 28, no. 571-572 (November 2017): 18–20. http://dx.doi.org/10.1016/s0992-5945(17)30266-0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Batard, Eric, and Gilles Potel. "Thérapeutique des infections à staphylocoques." EMC - Maladies infectieuses 3, no. 4 (January 2006): 1–8. http://dx.doi.org/10.1016/s1166-8598(06)41682-3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Pandey, Vivek, SripathiP Rao, Sugandhi Rao, KiranK V. Acharya, and SarabjeetSingh Chhabra. "Burkholderia pseudomalleimusculoskeletal infections (melioidosis) in India." Indian Journal of Orthopaedics 44, no. 2 (2010): 216. http://dx.doi.org/10.4103/0019-5413.61829.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Burns, Jane L., and Lisa Saiman. "BURKHOLDERIA CEPACIA INFECTIONS IN CYSTIC FIBROSIS." Pediatric Infectious Disease Journal 18, no. 2 (February 1999): 155–56. http://dx.doi.org/10.1097/00006454-199902000-00015.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Otağ, F., G. Ersöz, M. Şalcıoğlu, Ç. Bal, I. Schneider, and A. Bauernfeind. "Nosocomial bloodstream infections with Burkholderia stabilis." Journal of Hospital Infection 59, no. 1 (January 2005): 46–52. http://dx.doi.org/10.1016/j.jhin.2004.06.034.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Bedir Demirdag, Tugba, Aslinur Ozkaya Parlakay, Ismail Selcuk Aygar, Belgin Gulhan, and Saliha Kanik Yuksek. "Major Aspects of Burkholderia gladioli and Burkholderia cepacia Infections in Children." Pediatric Infectious Disease Journal 39, no. 5 (May 2020): 374–78. http://dx.doi.org/10.1097/inf.0000000000002587.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Wang, Guanbo, Paulina Zarodkiewicz, and Miguel A. Valvano. "Current Advances in Burkholderia Vaccines Development." Cells 9, no. 12 (December 11, 2020): 2671. http://dx.doi.org/10.3390/cells9122671.

Full text

Abstract:

The genus Burkholderia includes a wide range of Gram-negative bacterial species some of which are pathogenic to humans and other vertebrates. The most pathogenic species are Burkholderia mallei, Burkholderia pseudomallei, and the members of the Burkholderia cepacia complex (Bcc). B. mallei and B. pseudomallei, the cause of glanders and melioidosis, respectively, are considered potential bioweapons. The Bcc comprises a subset of Burkholderia species associated with respiratory infections in people with chronic granulomatous disease and cystic fibrosis. Antimicrobial treatment of Burkholderia infections is difficult due to the intrinsic multidrug antibiotic resistance of these bacteria; prophylactic vaccines provide an attractive alternative to counteract these infections. Although commercial vaccines against Burkholderia infections are still unavailable, substantial progress has been made over recent years in the development of vaccines against B. pseudomallei and B. mallei. This review critically discusses the current advances in vaccine development against B. mallei, B. pseudomallei, and the Bcc.

APA, Harvard, Vancouver, ISO, and other styles

10

Grund, Megan E., Jeon Soo, Christopher K. Cote, Rita Berisio, and Slawomir Lukomski. "Thinking Outside the Bug: Targeting Outer Membrane Proteins for Burkholderia Vaccines." Cells 10, no. 3 (February 25, 2021): 495. http://dx.doi.org/10.3390/cells10030495.

Full text

Abstract:

Increasing antimicrobial resistance due to misuse and overuse of antimicrobials, as well as a lack of new and innovative antibiotics in development has become an alarming global threat. Preventative therapeutics, like vaccines, are combative measures that aim to stop infections at the source, thereby decreasing the overall use of antibiotics. Infections due to Gram-negative pathogens pose a significant treatment challenge because of substantial multidrug resistance that is acquired and spread throughout the bacterial population. Burkholderia spp. are Gram-negative intrinsically resistant bacteria that are responsible for environmental and nosocomial infections. The Burkholderia cepacia complex are respiratory pathogens that primarily infect immunocompromised and cystic fibrosis patients, and are acquired through contaminated products and equipment, or via patient-to-patient transmission. The Burkholderia pseudomallei complex causes percutaneous wound, cardiovascular, and respiratory infections. Transmission occurs through direct exposure to contaminated water, water-vapors, or soil, leading to the human disease melioidosis, or the equine disease glanders. Currently there is no licensed vaccine against any Burkholderia pathogen. This review will discuss Burkholderia vaccine candidates derived from outer membrane proteins, OmpA, OmpW, Omp85, and Bucl8, encompassing their structures, conservation, and vaccine formulation.

APA, Harvard, Vancouver, ISO, and other styles

11

Olesen, H., A. Zolin, L. Viviani, M. Stern, and E. Kerem. "Burkholderia and Stenotrophomonas infections among different European countries." Journal of Cystic Fibrosis 9 (June 2010): S27. http://dx.doi.org/10.1016/s1569-1993(10)60103-8.

Full text

APA, Harvard, Vancouver, ISO, and other styles

12

Gunardi, Wani D., Kris H. Timotius, Agustine Natasha, and Paulina R. Evriarti. "Biofilm Targeting Strategy in the Eradication of Burkholderia Infections: A Mini-Review." Open Microbiology Journal 15, no. 1 (June 18, 2021): 51–57. http://dx.doi.org/10.2174/1874285802115010051.

Full text

Abstract:

Burkholderia are intracellular pathogenic bacteria which can produce biofilm. This biofilm protects the intracellular pathogenic bacteria from antibiotic treatment and the immunological system of the host. Therefore, this review aims to describe the capacity of Burkholderia to form a biofilm, the regulation of its biofilm formation, the efficacy of antibiotics to eradicate biofilm, and the novel therapy which targets its biofilm. Burkholderia's biofilm is characterized by its lipopolysaccharides, exopolysaccharides (EPSs), biofilm-associated proteins, and eDNA. Its regulation is made by quorum sensing, c-di-AMP, sRNA, and two component systems. Many antibiotics have been used as sole or mixture agents; however, they are not always effective in eradicating the biofilm-forming Burkholderia. Inhibitors of quorum sensing and other non-conventional antibiotic approaches are promising to discover effective treatment of Burkholderia infections.

APA, Harvard, Vancouver, ISO, and other styles

13

Mott, Tiffany, R. Johnston, Sudhamathi Vijayakumar, D. Estes, Massoud Motamedi, Elena Sbrana, Janice Endsley, and Alfredo Torres. "Monitoring Therapeutic Treatments against Burkholderia Infections Using Imaging Techniques." Pathogens 2, no. 2 (May 23, 2013): 383–401. http://dx.doi.org/10.3390/pathogens2020383.

Full text

APA, Harvard, Vancouver, ISO, and other styles

14

Trivedi, P., U. Tuteja, R. Khushiramani, Jain Reena, and H. V. Batra. "Development of a diagnostic system for Burkholderia pseudomallei infections." World Journal of Microbiology and Biotechnology 28, no. 7 (May 23, 2012): 2465–71. http://dx.doi.org/10.1007/s11274-012-1053-y.

Full text

APA, Harvard, Vancouver, ISO, and other styles

15

Chanal, Johan, François Lassau, Philippe Morand, Michel Janier, and Nicolas Dupin. "Actualités diagnostique et thérapeutique des infections à Neisseria gonorrhoeae." La Presse Médicale 42, no. 4 (April 2013): 454–58. http://dx.doi.org/10.1016/j.lpm.2012.09.023.

Full text

APA, Harvard, Vancouver, ISO, and other styles

16

Lynch, Karlene H., Kimberley D. Seed, Paul Stothard, and Jonathan J. Dennis. "Inactivation of Burkholderia cepacia Complex Phage KS9 gp41 Identifies the Phage Repressor and Generates Lytic Virions." Journal of Virology 84, no. 3 (November 25, 2009): 1276–88. http://dx.doi.org/10.1128/jvi.01843-09.

Full text

Abstract:

ABSTRACT The Burkholderia cepacia complex (BCC) is made up of at least 17 species of Gram-negative opportunistic bacterial pathogens that cause fatal infections in patients with cystic fibrosis and chronic granulomatous disease. KS9 (vB_BcenS_KS9), one of a number of temperate phages isolated from BCC species, is a prophage of Burkholderia pyrrocinia LMG 21824. Transmission electron micrographs indicate that KS9 belongs to the family Siphoviridae and exhibits the B1 morphotype. The 39,896-bp KS9 genome, comprised of 50 predicted genes, integrates into the 3′ end of the LMG 21824 GTP cyclohydrolase II open reading frame. The KS9 genome is most similar to uncharacterized prophage elements in the genome of B. cenocepacia PC184 (vB_BcenZ_ PC184), as well as Burkholderia thailandensis phage φE125 and Burkholderia pseudomallei phage φ1026b. Using molecular techniques, we have disrupted KS9 gene 41, which exhibits similarity to genes encoding phage repressors, producing a lytic mutant named KS9c. This phage is incapable of stable lysogeny in either LMG 21824 or B. cenocepacia strain K56-2 and rescues a Galleria mellonella infection model from experimental B. cenocepacia K56-2 infections at relatively low multiplicities of infection. These results readily demonstrate that temperate phages can be genetically engineered to lytic form and that these modified phages can be used to treat bacterial infections in vivo.

APA, Harvard, Vancouver, ISO, and other styles

17

Leong, Lex E. X., Diana Lagana, Glen P. Carter, Qinning Wang, Kija Smith, Tim P. Stinear, David Shaw, et al. "Burkholderia lata Infections from Intrinsically Contaminated Chlorhexidine Mouthwash, Australia, 2016." Emerging Infectious Diseases 24, no. 11 (November 2018): 2109–11. http://dx.doi.org/10.3201/eid2411.171929.

Full text

APA, Harvard, Vancouver, ISO, and other styles

18

Semler, Diana D., Amanda D. Goudie, Warren H. Finlay, and Jonathan J. Dennis. "Aerosol Phage Therapy Efficacy in Burkholderia cepacia Complex Respiratory Infections." Antimicrobial Agents and Chemotherapy 58, no. 7 (May 5, 2014): 4005–13. http://dx.doi.org/10.1128/aac.02388-13.

Full text

Abstract:

ABSTRACTPhage therapy has been suggested as a potential treatment for highly antibiotic-resistant bacteria, such as the species of theBurkholderia cepaciacomplex (BCC). To address this hypothesis, experimentalB. cenocepaciarespiratory infections were established in mice using a nebulizer and a nose-only inhalation device. Following infection, the mice were treated with one of fiveB. cenocepacia-specific phages delivered as either an aerosol or intraperitoneal injection. The bacterial and phage titers within the lungs were assayed 2 days after treatment, and mice that received the aerosolized phage therapy demonstrated significant decreases in bacterial loads. Differences in phage activity were observedin vivo. Mice that received phage treatment by intraperitoneal injection did not demonstrate significantly reduced bacterial loads, although phage particles were isolated from their lung tissue. Based on these data, aerosol phage therapy appears to be an effective method for treating highly antibiotic-resistant bacterial respiratory infections, including those caused by BCC bacteria.

APA, Harvard, Vancouver, ISO, and other styles

19

Raja, Nadeem Sajjad, and Christine Scarsbrook. "Burkholderia Pseudomallei Causing Bone and Joint Infections: A Clinical Update." Infectious Diseases and Therapy 5, no. 1 (January 4, 2016): 17–29. http://dx.doi.org/10.1007/s40121-015-0098-2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

Loutet, Slade A., and Miguel A. Valvano. "A Decade of Burkholderia cenocepacia Virulence Determinant Research." Infection and Immunity 78, no. 10 (July 19, 2010): 4088–100. http://dx.doi.org/10.1128/iai.00212-10.

Full text

Abstract:

ABSTRACT The Burkholderia cepacia complex (Bcc) is a group of genetically related environmental bacteria that can cause chronic opportunistic infections in patients with cystic fibrosis (CF) and other underlying diseases. These infections are difficult to treat due to the inherent resistance of the bacteria to antibiotics. Bacteria can spread between CF patients through social contact and sometimes cause cepacia syndrome, a fatal pneumonia accompanied by septicemia. Burkholderia cenocepacia has been the focus of attention because initially it was the most common Bcc species isolated from patients with CF in North America and Europe. Today, B. cenocepacia, along with Burkholderia multivorans, is the most prevalent Bcc species in patients with CF. Given the progress that has been made in our understanding of B. cenocepacia over the past decade, we thought that it was an appropriate time to review our knowledge of the pathogenesis of B. cenocepacia, paying particular attention to the characterization of virulence determinants and the new tools that have been developed to study them. A common theme emerging from these studies is that B. cenocepacia establishes chronic infections in immunocompromised patients, which depend more on determinants mediating host niche adaptation than those involved directly in host cells and tissue damage.

APA, Harvard, Vancouver, ISO, and other styles

21

Bansal, Sharad, Rambabu Sharma, and Narendra Jangir. "Pattern of clinical manifestation and antibiotics sensitivity of Burkholderia Cepacia sepsis in Neonatal Intensive Care Unit of tertiary care centre of North India." International Journal of Contemporary Pediatrics 6, no. 6 (October 21, 2019): 2650. http://dx.doi.org/10.18203/2349-3291.ijcp20194748.

Full text

Abstract:

Background: Neonatal sepsis is a major cause of morbidity and mortality worldwide. Now a days, neonatal sepsis due to Burkholderia cepacia is on rise. This study was conducted to delineate clinical presentation and antibiotic sensitivity pattern from blood culture proven Burkholderia sepsis. Methods: In this retrospective analytical study, thirty-six neonates admitted to Neonatal Intensive Care Unit of a tertiary care hospital with blood culture proven Burkholderia sepsis were included. Clinical manifestation, laboratory findings and antibiotic sensitivity patterns of blood culture proven Burkholderia sepsis were analyzed.Results: : All neonates were inborn and were admitted within 24 hours of birth. Difficulty in breathing was most common presenting symptom and seizure was second in number. There was no association with mode of delivery. Male to female ratio is 1.4:1. Progressive thrombocytopenia was the most consistent feature and in 6 patients also associated with anaemia. Average hospital stay was increased and more in preterm neonates. In this setup piperacillin + tazobactem was found to be most sensitive against Burkholderia cepacia and cotrimoxazole was 2nd in sensitivity.Conclusions: Proper and timely identification of Non Fermentative Gram Negative Bacilli (NFGNB) other than Pseudomonas can help confine morbidity due to such infections. High degree of suspicion helps in early recognition. Efficient housekeeping is necessary to prevent nosocomial infections due to these pathogens.

APA, Harvard, Vancouver, ISO, and other styles

22

Harf-Monteil, C., J. Gaudias, J. Loichot, and H. Monteil. "Infections de plaies à Aeromonas : un piège diagnostique et thérapeutique." Médecine et Maladies Infectieuses 33, no. 11 (November 2003): 590–92. http://dx.doi.org/10.1016/s0399-077x(03)00003-9.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

Gerber, V., B. Dimitrov, V. Greigert, M. Mohseni, G. M. Pelami, P. David, P. Keller, and M. Martinot. "Analyse clinique, microbiologique et thérapeutique des infections de prothèse abdominale." Médecine et Maladies Infectieuses 48, no. 4 (June 2018): S84—S85. http://dx.doi.org/10.1016/j.medmal.2018.04.211.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

Mongardon, N., and A. Cariou. "Hypothermie thérapeutique après arrêt cardiaque et infections acquises en réanimation." Réanimation 24, no. 3 (March 23, 2015): 224–35. http://dx.doi.org/10.1007/s13546-015-1045-7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

Majerczyk, Charlotte, Loren Kinman, Tony Han, Richard Bunt, and E. Peter Greenberg. "Virulence of Burkholderia mallei Quorum-Sensing Mutants." Infection and Immunity 81, no. 5 (February 19, 2013): 1471–78. http://dx.doi.org/10.1128/iai.00048-13.

Full text

Abstract:

ABSTRACTManyProteobacteriause acyl-homoserine lactone-mediated quorum-sensing (QS) to activate specific sets of genes as a function of cell density. QS often controls the virulence of pathogenic species, and in fact a previous study indicated that QS was important forBurkholderia malleimouse lung infections. To gain in-depth information on the role of QS inB. malleivirulence, we constructed and characterized a mutant ofB. malleistrain GB8 that was unable to make acyl-homoserine lactones. The QS mutant showed virulence equal to that of its wild-type parent in an aerosol mouse infection model, and growth in macrophages was indistinguishable from that of the parent strain. Furthermore, we assessed the role of QS inB. malleiATCC 23344 by constructing and characterizing a mutant strain producing AiiA, a lactonase enzyme that degrades acyl-homoserine lactones. Although acyl-homoserine lactone levels in cultures of this strain are very low, it showed full virulence. Contrary to the previous report, we conclude that QS is not required for acuteB. malleiinfections of mice. QS may be involved in some stage of chronic infections in the natural host of horses, or the QS genes may be remnants of the QS network inB. pseudomalleifrom which this host-adapted pathogen evolved.

APA, Harvard, Vancouver, ISO, and other styles

26

Mootien, J. Y., and J. R. Zahar. "Entérobactéries productrices de carbapénémases en médecine intensive : thérapeutique." Médecine Intensive Réanimation 27, no. 4 (July 2018): 372–80. http://dx.doi.org/10.3166/rea-2018-0058.

Full text

Abstract:

Les infections à entérobactéries productrices de carbapénémases peuvent représenter une pathologie redoutable, notamment dans les situations cliniques graves, en raison des possibilités thérapeutiques limitées. En France, les mécanismes OXA-48 et OXA-48-like (78 %) sont les plus fréquemment retrouvés. Les stratégies thérapeutiques actuelles limitées ont mis en exergue l’intérêt de certaines vieilles molécules et des associations d’antibiotiques avec une optimisation de leurs modalités d’administration. Dans l’attente de l’apport des futures options thérapeutiques, les essais contrôlés randomisés sont plus que nécessaires. Nous devons nous inspirer de l’expérience de ceux qui prennent en charge ces infections. La maîtrise du bon usage des antibiotiques reste toujours d’actualité afin de préserver l’efficacité des molécules existantes.

APA, Harvard, Vancouver, ISO, and other styles

27

RAJASEKHARAN, SATISH KUMAR, and SAMIRAJ RAMESH. "Cellulase Inhibits Burkholderia cepacia Biofilms on Diverse Prosthetic Materials." Polish Journal of Microbiology 62, no. 3 (2013): 327–30. http://dx.doi.org/10.33073/pjm-2013-044.

Full text

Abstract:

Burkholderia cepacia is an opportunistic pathogen causing infections in patients with cystic fibrosis. Patients with implanted devices are prone to B. cepacia infections due to its ability to grow as biofilms. Knowing the importance of polysaccharides in a biofilm, enzymes that degrade them were targeted as a possible candidate for antibiofilm agents. In this study, the antibiofilm potential of cellulase against B. cepacia biofilms formed on various prosthetic materials was tested. Cellulase exhibited significant antibiofilm activity against B. cepacia without having much action on its growth, thus ruling out the chance of selection pressure and subsequent development resistance.

APA, Harvard, Vancouver, ISO, and other styles

28

Sousa, Sílvia A., António M. M. Seixas, Joana M. M. Marques, and Jorge H. Leitão. "Immunization and Immunotherapy Approaches against Pseudomonas aeruginosa and Burkholderia cepacia Complex Infections." Vaccines 9, no. 6 (June 18, 2021): 670. http://dx.doi.org/10.3390/vaccines9060670.

Full text

Abstract:

Human infections caused by the opportunist pathogens Burkholderia cepacia complex and Pseudomonas aeruginosa are of particular concern due to their severity, their multiple antibiotic resistance, and the limited eradication efficiency of the current available treatments. New therapeutic options have been pursued, being vaccination strategies to prevent or limit these infections as a rational approach to tackle these infections. In this review, immunization and immunotherapy approaches currently available and under study against these bacterial pathogens is reviewed. Ongoing active and passive immunization clinical trials against P. aeruginosa infections is also reviewed. Novel identified bacterial targets and their possible exploitation for the development of immunization and immunotherapy strategies against P. aeruginosa and B. cepacia complex and infections are also presented and discussed.

APA, Harvard, Vancouver, ISO, and other styles

29

Shaban, Ramon Z., Cristina Sotomayor-Castillo, Shizar Nahidi, Cecilia Li, Deborough Macbeth, Brett G. Mitchell, and Philip L. Russo. "Global burden, point sources, and outbreak management of healthcare-associated Burkholderia cepacia infections: An integrative review." Infection Control & Hospital Epidemiology 41, no. 7 (May 22, 2020): 777–83. http://dx.doi.org/10.1017/ice.2020.184.

Full text

Abstract:

AbstractObjective:To examine the global burden, associated point sources, and successful prevention and control measures for documented outbreaks of Burkholderia cepacia healthcare-associated infections (HAIs).Design:Integrative review.Methods:A review of all outbreaks of Burkholderia cepacia HAIs published in the peer-reviewed literature between January 1970 and October 2019 was conducted to identify the global burden, associated point sources, and successful prevention and control measures using the Guidelines for Outbreak Reports and Intervention Studies of Nosocomial Infections (ORION).Results:In total, we reviewed 125 documented outbreaks of Burkholderia cepacia–related HAIs worldwide. The reported B. cepacia HAIs for this period involved 3,287 patients. The point sources were identified in most outbreaks of B. cepacia HAIs (n = 93; 74.4%); they included medication vials, disinfectants, and antiseptics. Moreover, 95 of the outbreak reports (76%) described effective prevention and control measures, but only 33 reports indicated the use of a combination of environment-, patient- and staff-related measures. None of the outbreak reports used the ORION guidelines.Conclusions:Outbreaks of Burkholderia cepacia HAIs are an ongoing challenge. They are often associated with immunocompromised patients who acquire the infection from exposure to contaminated medications, products, and equipment. These outbreaks are not infrequent, and a range of infection prevention and control measures have been effective in arresting spread. The use of ORION guidelines for outbreak reporting would improve the quality of information and data to generate evidence for translation into practice.

APA, Harvard, Vancouver, ISO, and other styles

30

Wong, Min Yi, Yuan-Hsi Tseng, Tsung-Yu Huang, Bor-Shyh Lin, Chun-Wu Tung, Chishih Chu, and Yao-Kuang Huang. "Comparison of Microbiological Characteristics and Genetic Diversity between Burkholderia cepacia Complex Isolates from Vascular Access and Other Clinical Infections." Microorganisms 9, no. 1 (December 27, 2020): 51. http://dx.doi.org/10.3390/microorganisms9010051.

Full text

Abstract:

Burkholderia cepacia complex (BCC) is a group of closely related bacteria with widespread environmental distribution. BCC bacteria are opportunistic pathogens that cause nosocomial infections in patients, especially cystic fibrosis (CF). Multilocus sequence typing (MLST) is used nowadays to differentiate species within the BCC complex. This study collected 41 BCC isolates from vascular access infections (VAIs) and other clinical infections between 2014 and 2020. We preliminarily identified bacterial isolates using standard biochemical procedures and further conducted recA gene sequencing and MLST for species identification. We determined genetic diversity indices using bioinformatics software. We studied 14 isolates retrieved from patients with VAIs and observed that Burkholderia cepacia was the predominant bacterial species, and B. contaminans followed by B. cenocepacia were mainly retrieved from patients with other infections. According to MLST data, we identified that all B. contaminans isolates belonged to ST102, while a wide variety of sequence types (STs) were found in B. cenocepacia isolates. In summary, the high diversity and easy transmission of BCC increase BCC infections, which provides insights into their potential clinical effects in non-CF infections.

APA, Harvard, Vancouver, ISO, and other styles

31

Zakharova, I. B., A. V. Toporkov, and D. V. Viktorov. "MELIOIDOSIS AND GLANDERS: CURRENT STATE AND ACTUAL ISSUES OF EPIDEMIOLOGICAL SURVEILLANCE." Journal of microbiology epidemiology immunobiology, no. 6 (December 28, 2018): 103–9. http://dx.doi.org/10.36233/0372-9311-2018-6-103-109.

Full text

Abstract:

Burkholderia pseudomallei and Burkholderia mallei are etiologic agents of glanders and melioidosis, the particularly dangerous infections of animals and humans, and are attributed to potential agents of bioterrorism. The manifestation of diseases ranges from acute septicemia to chronic infection, any organs and tissues are affected, andtreatment requires long intravenous and oral antibiotic courses. The endemic zone of glanders and melioidosis covers spacious regions in the world, and the number of imported cases to temperate regions is constantly increasing. For the Russian Federation, glanders and melioidosis are «forgotten» and «unknown» infections, and this review presents current data on their distribution in the world, epidemiological aspects, and laboratory diagnosis features.

APA, Harvard, Vancouver, ISO, and other styles

32

Vonberg, Ralf-Peter, Susanne Häußler, Peter Vandamme, and Ivo Steinmetz. "Identification of Burkholderia cepacia complex pathogens by rapid-cycle PCR with fluorescent hybridization probes." Journal of Medical Microbiology 55, no. 6 (June 1, 2006): 721–27. http://dx.doi.org/10.1099/jmm.0.46457-0.

Full text

Abstract:

Members of the Burkholderia cepacia complex are important bacterial pathogens in cystic fibrosis (CF) patients. The B. cepacia complex currently consists of nine genetic subgroups (genomovars) of different epidemiological relevance and possibly of different pathogenic potential in humans. In this study, a new approach was developed for the rapid identification of B. cepacia genomovar I, Burkholderia multivorans (genomovar II), Burkholderia cenocepacia (lineage III-A and III-B), Burkholderia stabilis (genomovar IV) and Burkholderia vietnamiensis (genomovar V), which cause the large majority of infections in CF patients. The method was based on the detection of differences in the recA gene sequence by using rapid-cycle PCR and genomovar-specific fluorescence resonance energy transfer (FRET) probes. The genomovar status of all 39 B. cepacia complex strains tested (genomovars I–V) was identified by melting-curve analysis. Each FRET probe produced a specific fluorescence signal only with the respective genomovar, and not with other B. cepacia complex strains and Burkholderia spp. The identification system was easy to handle and revealed B. cepacia complex genomovar I–V status from culture isolates within about 1 h.

APA, Harvard, Vancouver, ISO, and other styles

33

Hasan, Zahidul, Md Kamrul Islam, and Arifa Hossain. "Healthcare associated infections caused by non-fermenting Gram negative rods (NFGNR): six years of experience of a tertiary hospital." Bangladesh Journal of Medical Microbiology 7, no. 2 (July 1, 2013): 06–12. http://dx.doi.org/10.3329/bjmm.v7i2.19326.

Full text

Abstract:

Recently non-fermenting Gram negative rods (NFGNR) are playing an important role in healthcare associated infections. This observational study in a tertiary care hospital of Dhaka city conducted during 01August 2007 to 30 June 2013 found that 34.8% isolated organisms from patients with healthcare associated infections were NFGNR. Majority (74.3 %) of these infections were occurring inside critical care areas. Pseudomonas and Acinetobacter together constituted 79.6% of the total NFGNR whereas Burkholderia cephacia complex (15.4%), Stenotrophomonas (4.3%) and Chryseobacterium species (0.7%) combined constituted remaining 20.4%. Out of total NFGNRs, Pseudomonas was responsible for highest number of catheter associated urinary tract infections (55.6%), ventilator associated pneumonia (46.3%), respiratory tract infection (65.8%) and surgical site infection (70.6%). Blood stream infection was predominantly caused by Burkholderia cephacia complex (33.5%) and Acinetobacter spp. (39.5%). Other than colistin most of the organisms were resistant to antibiotics commonly recommended for NFGNR.DOI: http://dx.doi.org/10.3329/bjmm.v7i2.19326 Bangladesh J Med Microbiol 2013; 07(02): 6-12

APA, Harvard, Vancouver, ISO, and other styles

34

Sfeir, Maroun M. "Burkholderia cepacia complex infections: More complex than the bacterium name suggest." Journal of Infection 77, no. 3 (September 2018): 166–70. http://dx.doi.org/10.1016/j.jinf.2018.07.006.

Full text

APA, Harvard, Vancouver, ISO, and other styles

35

Gleeson, Sarah, Eoin Mulroy, Elizabeth Bryce, Sally Fox, Susan L. Taylor, and Hari Talreja. "Burkholderia cepacia: An Outbreak in the Peritoneal Dialysis Unit." Peritoneal Dialysis International: Journal of the International Society for Peritoneal Dialysis 39, no. 1 (January 2019): 92–95. http://dx.doi.org/10.3747/pdi.2018.00095.

Full text

Abstract:

Burkholderia cepacia is a ubiquitous, opportunistic, environmental gram-negative bacillus which most commonly affects cystic fibrosis and immunocompromised patients. Rarely, it can cause peritoneal dialysis (PD) exit-site infection (ESI). Information relating to predisposing factors, clinical course, and treatment options for B. cepacia ESIs is limited. Although reports of B. cepacia healthcare-associated infections exist, outbreaks in PD units have not previously been reported. A recent outbreak of B. cepacia ESI in our PD unit provided a unique opportunity to study B. cepacia ESIs and to outline an approach to investigating such an outbreak. After unexpectedly identifying B. cepacia as the cause of PD catheter ESIs in 3 patients over an 11-week period, we began systematically screening our PD population for B. cepacia exit-site colonization. A further 6 patients were found to be affected, 3 with asymptomatic colonization and 3 with symptomatic B. cepacia ESI. Four of the 6 developed tunnel infections requiring multiple courses of antibiotic treatment, and 3 patients required catheter removal; 2 patients with symptomatic ESIs without tunnel involvement responded to oral and topical antibiotics. Further investigation implicated 4% chlorhexidine aqueous bodywash used by all patients as the probable source of the outbreak. This is the first reported outbreak of B. cepacia ESIs. We noted an association between diabetes mellitus and refractory/more extensive infection. Our experience suggests that isolated ESIs can be treated successfully with oral antibiotics whereas tunnel infections generally require catheter removal.

APA, Harvard, Vancouver, ISO, and other styles

36

Padoin, C. "Intérêt du suivi thérapeutique pharmacologique dans le cadre des infections pulmonaires." Revue des Maladies Respiratoires 34, no. 6 (June 2017): 693–705. http://dx.doi.org/10.1016/j.rmr.2016.08.008.

Full text

APA, Harvard, Vancouver, ISO, and other styles

37

Couzigou, C., and B. Misset. "Infections nosocomiales : conduite à tenir et stratégie thérapeutique devant une épidémie." EMC - Anesthésie-Réanimation 9, no. 1 (January 2012): 1–9. http://dx.doi.org/10.1016/s0246-0289(12)70033-6.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

Besnier, J. M., F. Bastides, and P. Choutet. "Thérapeutique des infections à Staphylococcus aureus sensible à la méticilline (SAMS)." Médecine et Maladies Infectieuses 27 (March 1997): 225–40. http://dx.doi.org/10.1016/s0399-077x(97)80024-8.

Full text

APA, Harvard, Vancouver, ISO, and other styles

39

Domart, Y. "Thérapeutique des infections à Staphylococcus aureus résistant à la méticilline (SAMR)." Médecine et Maladies Infectieuses 27 (March 1997): 241–51. http://dx.doi.org/10.1016/s0399-077x(97)80025-x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

40

Cattoen, C., and A. Boruchowicz. "Diagnostic et prise en charge thérapeutique des infections à Clostridium difficile." Antibiotiques 9, no. 4 (December 2007): 278–83. http://dx.doi.org/10.1016/s1294-5501(07)73927-4.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

Knani, H., W. Marrakchi, I. Kooli, H. Ben Brahim, A. Toumi, A. Aouam, and M. Chakroun. "Particularités épidémio-cliniques et thérapeutique des infections urinaires chez les diabétiques." Annales d'Endocrinologie 81, no. 4 (September 2020): 430. http://dx.doi.org/10.1016/j.ando.2020.07.822.

Full text

APA, Harvard, Vancouver, ISO, and other styles

42

Munier, A. L., and V. Leflon-Guibout. "Infections à Campylobacter : tableaux cliniques, prise en charge diagnostique et thérapeutique." Journal des Anti-infectieux 18, no. 4 (December 2016): 169–76. http://dx.doi.org/10.1016/j.antinf.2016.09.004.

Full text

APA, Harvard, Vancouver, ISO, and other styles

43

Sousa, Sílvia A., António M. M. Seixas, Manoj Mandal, Manuel J. Rodríguez-Ortega, and Jorge H. Leitão. "Characterization of the Burkholderia cenocepacia J2315 Surface-Exposed Immunoproteome." Vaccines 8, no. 3 (September 6, 2020): 509. http://dx.doi.org/10.3390/vaccines8030509.

Full text

Abstract:

Infections by the Burkholderia cepacia complex (Bcc) remain seriously life threatening to cystic fibrosis (CF) patients, and no effective eradication is available. A vaccine to protect patients against Bcc infections is a highly attractive therapeutic option, but none is available. A strategy combining the bioinformatics identification of putative surface-exposed proteins with an experimental approach encompassing the “shaving” of surface-exposed proteins with trypsin followed by peptide identification by liquid chromatography and mass spectrometry is here reported. The methodology allowed the bioinformatics identification of 263 potentially surface-exposed proteins, 16 of them also experimentally identified by the “shaving” approach. Of the proteins identified, 143 have a high probability of containing B-cell epitopes that are surface-exposed. The immunogenicity of three of these proteins was demonstrated using serum samples from Bcc-infected CF patients and Western blotting, validating the usefulness of this methodology in identifying potentially immunogenic surface-exposed proteins that might be used for the development of Bcc-protective vaccines.

APA, Harvard, Vancouver, ISO, and other styles

44

Saldías, M. Soledad, and Miguel A. Valvano. "Interactions of Burkholderia cenocepacia and other Burkholderia cepacia complex bacteria with epithelial and phagocytic cells." Microbiology 155, no. 9 (September 1, 2009): 2809–17. http://dx.doi.org/10.1099/mic.0.031344-0.

Full text

Abstract:

Burkholderia cenocepacia is a member of the B. cepacia complex (Bcc), a group of opportunistic bacteria that infect the airways of patients with cystic fibrosis (CF) and are extraordinarily resistant to almost all clinically useful antibiotics. Infections in CF patients with Bcc bacteria generally lead to a more rapid decline in lung function, and in some cases to the ‘cepacia syndrome’, a virtually deadly exacerbation of the lung infection with systemic manifestations. These characteristics of Bcc bacteria contribute to higher morbidity and mortality in infected CF patients. In the last 10 years considerable progress has been made in understanding the interactions between Bcc bacteria and mammalian host cells. Bcc isolates can survive either intracellularly within eukaryotic cells or extracellularly in host tissues. They survive within phagocytes and respiratory epithelial cells, and they have the ability to breach the respiratory epithelium layer. Survival and persistence of Bcc bacteria within host cells and tissues are believed to play a key role in pulmonary infection and to contribute to the persistent inflammation observed in patients with CF. This review summarizes recent findings concerning the interaction between Bcc bacteria and epithelial and phagocytic cells.

APA, Harvard, Vancouver, ISO, and other styles

45

AuCoin, David P., Reva B. Crump, Peter Thorkildson, Dana E. Nuti, John J. LiPuma, and Thomas R. Kozel. "Identification of Burkholderia cepacia complex bacteria with a lipopolysaccharide-specific monoclonal antibody." Journal of Medical Microbiology 59, no. 1 (January 1, 2010): 41–47. http://dx.doi.org/10.1099/jmm.0.012500-0.

Full text

Abstract:

The genus Burkholderia includes many bacteria that cause serious human infections. As is the case with other Gram-negative bacteria, Burkholderia species produce LPS, which is an abundant component of the bacterial cell surface. Burkholderia cepacia complex (Bcc) bacteria (which include at least 17 separate species) produce LPS structures that are quite different. In an attempt to determine the degree of LPS epitope variation among Bcc species, a mAb was produced, designated 5D8, specific for the LPS of B. cepacia. Western blot analysis determined that mAb 5D8 was able to produce the classic ‘ladder pattern’ when used to probe B. cepacia and Burkholderia anthina lysates, although 5D8 did not produce this pattern with the other seven Bcc species tested. mAb 5D8 reacted with varying intensity to most but not all of the additional B. cepacia and B. anthina strains tested. Therefore, there seems to be significant epitope variation among Bcc LPS both between and within species. Additionally, mAb 5D8 reacted with a proteinase-K-sensitive 22 kDa antigen in all Bcc strains and also in a strain of Burkholderia pseudomallei.

APA, Harvard, Vancouver, ISO, and other styles

46

Caballero-Mellado, Jesús, Janette Onofre-Lemus, Paulina Estrada-de los Santos, and Lourdes Martínez-Aguilar. "The Tomato Rhizosphere, an Environment Rich in Nitrogen-Fixing Burkholderia Species with Capabilities of Interest for Agriculture and Bioremediation." Applied and Environmental Microbiology 73, no. 16 (June 29, 2007): 5308–19. http://dx.doi.org/10.1128/aem.00324-07.

Full text

Abstract:

ABSTRACT Burkholderia strains are promising candidates for biotechnological applications. Unfortunately, most of these strains belong to species of the Burkholderia cepacia complex (Bcc) involved in human infections, hampering potential applications. Novel diazotrophic Burkholderia species, phylogenetically distant from the Bcc species, have been discovered recently, but their environmental distribution and relevant features for agro-biotechnological applications are little known. In this work, the occurrence of N2-fixing Burkholderia species in the rhizospheres and rhizoplanes of tomato plants field grown in Mexico was assessed. The results revealed a high level of diversity of diazotrophic Burkholderia species, including B. unamae, B. xenovorans, B. tropica, and two other unknown species, one of them phylogenetically closely related to B. kururiensis. These N2-fixing Burkholderia species exhibited activities involved in bioremediation, plant growth promotion, or biological control in vitro. Remarkably, B. unamae and B. kururiensis grew with aromatic compounds (phenol and benzene) as carbon sources, and the presence of aromatic oxygenase genes was confirmed in both species. The rhizospheric and endophyte nature of B. unamae and its ability to degrade aromatic compounds suggest that it could be used in rhizoremediation and for improvement of phytoremediation. B. kururiensis and other Burkholderia sp. strains grew with toluene. B. unamae and B. xenovorans exhibited ACC (1-aminocyclopropane-1-carboxylic acid) deaminase activity, and the occurrence of acdS genes encoding ACC deaminase was confirmed. Mineral phosphate solubilization through organic acid production appears to be the mechanism used by most diazotrophic Burkholderia species, but in B. tropica, there presumably exists an additional unknown mechanism. Most of the diazotrophic Burkholderia species produced hydroxamate-type siderophores. Certainly, the N2-fixing Burkholderia species associated with plants have great potential for agro-biotechnological applications.

APA, Harvard, Vancouver, ISO, and other styles

47

Sarkar, Mandira, Jagadananda Jena, Dipti Pattnaik, and Bandana Mallick. "Prevalence of nonfermentative gram-negative bacilli and their antimicrobial susceptibility profiles in a tertiary care hospital of Eastern India." International Journal of Advances in Medicine 5, no. 2 (March 21, 2018): 366. http://dx.doi.org/10.18203/2349-3933.ijam20181070.

Full text

Abstract:

Background: Nonfermentative gram-negative bacilli (nonfermenters) have emerged as a major concern for nosocomial infections. They exhibit resistance not only to the beta-lactam and other group of antibiotics but also to carbapenems. This study was undertaken to know the prevalence of nonfermenters from clinical samples along with their antimicrobial susceptibility profile.Methods: A cross-sectional study over a period of 21 months in the microbiology laboratory of a tertiary care hospital was done. Clinical samples were processed by conventional bacteriological methods for isolation and identification. Susceptibility testing was done by Kirby-Bauer disc diffusion method as recommended by Clinical and Laboratory Standard Institute.Results: 411 nonfermenters (13.18%) were isolated from 3116 culture positive clinical samples. Out of these nonfermenters, most were Acinetobacter baumannii (51.34%) followed by Pseudomonas aeruginosa (42.09%), Burkholderia cepacia complex (4.38%) and others (2.19%). Others included Burkholderia pseudomellei, Acinetobacter lwoffii and Stenotrophomonas maltophilia. Highest sensitivity to gentamicin and amikacin were shown by A. baumannii and P. aeruginosa respectively while both were mostly resistant to ceftriaxone. Burkholderia and Stenotrophomonas species showed 100% sensitivity to cotrimoxazole. A. baumannii was the most prevalent nonfermenter in intensive care units.Conclusions: Timely identification of nonfermenters and monitoring their susceptibility patterns will help in proper management of infections caused by them. Improved antibiotic stewardship and infection control measures should be implemented to prevent nosocomial infections and spread of drug resistant nonfermenters.

APA, Harvard, Vancouver, ISO, and other styles

48

Riedel, Kathrin, Manuela Köthe, Bernd Kramer, Wael Saeb, Astrid Gotschlich, Aldo Ammendola, and Leo Eberl. "Computer-Aided Design of Agents That Inhibit the cep Quorum-Sensing System of Burkholderia cenocepacia." Antimicrobial Agents and Chemotherapy 50, no. 1 (January 2006): 318–23. http://dx.doi.org/10.1128/aac.50.1.318-323.2006.

Full text

Abstract:

ABSTRACT Recent research has provided evidence that interference with bacterial cell-to-cell signaling is a promising strategy for the development of novel antimicrobial agents. Here we report on the computer-aided design of novel compounds that specifically inhibit an N-acyl-homoserine lactone-dependent communication system that is widespread among members of the genus Burkholderia. This genus comprises more than 30 species, many of which are important pathogens of animals and humans. Over the past few years, several Burkholderia species, most notably Burkholderia cenocepacia, have emerged as important opportunistic pathogens causing severe pulmonary deterioration in persons with cystic fibrosis. As efficient treatment of Burkholderia infections is hampered by the inherent resistance of the organisms to a large range of antibiotics, novel strategies for battling these pathogens need to be developed. Here we show that compounds targeting the B. cenocepacia signaling system efficiently inhibit the expression of virulence factors and attenuate the pathogenicity of the organism.

APA, Harvard, Vancouver, ISO, and other styles

49

Capelli, Riccardo, Elena Matterazzo, Marco Amabili, Claudio Peri, Alessandro Gori, Paola Gagni, Marcella Chiari, et al. "Designing Probes for Immunodiagnostics: Structural Insights into an Epitope Targeting Burkholderia Infections." ACS Infectious Diseases 3, no. 10 (July 21, 2017): 736–43. http://dx.doi.org/10.1021/acsinfecdis.7b00080.

Full text

APA, Harvard, Vancouver, ISO, and other styles

50

Berthelot, P., F. Grattard, F. O. Mallaval, A. Ros, F. Lucht, and B. Pozzetto. "Épidémiologie des infections nosocomiales à Pseudomonas aeruginosa, Burkholderia cepacia et Stenotrophomonas maltophilia." Pathologie Biologie 53, no. 6 (July 2005): 341–48. http://dx.doi.org/10.1016/j.patbio.2004.09.006.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Journal articles on the topic 'Infections à Burkholderia – Thérapeutique'

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles